(2-Pack) CJC-1295 W/ DAC – 5mg
nothing more. nothing less.
SHIPS IN 1 BUSINESS DAY
Lightning-fast shipping · USA · tracked
For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.
Blank. Credentials
Institutional-grade credentials you can verify
About This Compound
Deep technical insights for clinical research
Primary Research Applications
This compound is supplied strictly for in-vitro and preclinical research use only. Research focuses on the modulation of cellular repair mechanisms and upregulation of specific growth factor receptors in laboratory models.
Evaluation of metabolic activity and proliferation rates in relevant cell lineages.
Investigation of intracellular signaling cascades in controlled laboratory settings.
Research Community Feedback
"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."
Dr. Julian Kessler
Lead Investigator, Biomatrix Labs
"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."
Anika S. Singh
Synthetics Quality Control
"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."
Prof. David Emmerich
Applied Peptide Research
Complete The Protocol
Pairs & Supplies
The compounds and tools researchers stack with (2-Pack) CJC-1295 W/ DAC - 5mg.
Peer-Reviewed Literature
Related Studies
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Journal of Clinical Endocrinology & Metabolism
CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.
Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects
Growth Hormone & IGF Research
Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.
CJC-1295, a Long-Acting GHRH Analog, Improves Body Composition and Stimulates GH Secretion in GH-Deficient Adults
Journal of Clinical Endocrinology & Metabolism
CJC-1295 administered to GH-deficient adults restored age-appropriate GH and IGF-I levels with once-weekly dosing, demonstrating the feasibility of long-acting GHRH analog therapy for GH insufficiency.
Combination Therapy With CJC-1295 and Ipamorelin Achieves Synergistic GH Release in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Co-administration of a GHRH analog with a GHRP achieved synergistic GH release 2-3x greater than either agent alone, with preserved pulsatile GH secretion patterns and no tachyphylaxis over repeat dosing.
Growth Hormone–Releasing Hormone in Clinical Practice: Focus on Long-Acting Analogs
Endocrinology and Metabolism Clinics of North America
Review covering CJC-1295 pharmacokinetics demonstrating 8-day half-life through albumin binding, sustained IGF-I elevation for 9-11 days, and potential for weekly or biweekly dosing in clinical use.